Airbnb’s Stock Rises 15% On Strong Financial Results
Airbnb’s (ABNB) stock is up 15% after the home rental company reported better-than-expected financial results for the fourth quarter of last year.The San Francisco-based company announced earnings per share (EPS) of $0.73 U.S., which was well ahead of the $0.58 U.S. forecast on Wall Street. Revenue in the October through December quarter totaled $2.48 billion U.S., which topped the analyst consensus estimate of $2.43 billion U.S. Sales were up 12% from a year earlier.Management at Airbnb attributed the strong results to a continued recovery in the global travel industry coming out of the Covid-19 pandemic. In Q4 2024, the company reported 111 million nights and experiences booked, up 12% from a year ago. Gross booking value, which Airbnb uses to report host earnings, totaled $17.60 billion U.S. in the quarter, above expectations of $17.20 billion U.S.In terms of forward guidance, Airbnb said it expects to report revenue of $2.23 billion U.S. to $2.27 billion U.S. in the current first quarter of 2025. Analysts expected $2.30 billion U.S. Airbnb continues to buyback its own stock, purchasing $838 million U.S. of shares in Q4 and $3.40 billion U.S. for all of last year.Prior to today (Feb. 14), Airbnb’s stock had declined 5% over the last 12 months to trade at $141.04 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


